Mivavotinib

N/A

Report date: 2023/05/05 18:02:55
NME

Base Information

Drug NameMivavotinib
Drug Alias NameTAK-659CB-659
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3Spleen tyrosine kinase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[9] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterCalithera Biosciences IncNorthwestern University
Inactive CompaniesMillennium Pharmaceuticals IncTakeda Pharmaceutical Co Ltd
Active IndicationsSolid tumoursOvarian NeoplasmsCarcinoma, Ovarian Epithelial +[8] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[5] 

Other Information

ATC CodeN/A
Related LinksN/A